News | November 15, 2023
Natco Pharma posts consolidated Q2F Y24 PAT of Rs. 369 Cr
Natco Pharma has reported total income of Rs. 1060.8 crores during the period ended September 30, 2023
Natco Pharma has reported total income of Rs. 1060.8 crores during the period ended September 30, 2023
Solara Active Pharma Sciences has reported total income of Rs. 426.42 crores during the period ended September 30, 2023
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ
Likmez oral suspension is the first and only FDA-approved liquid option for patients with adherence hurdles such as dysphagia, difficulty swallowing
Phase 3 data expected in the second half of 2024
he company posted total income during Q2 FY24 at Rs. 12.86 crore
European operations' revenue grew 58.4% to Rs 599.7 crore
US business grew by +12.8% YoY
This collaboration underscores WOTR's unwavering commitment to strengthening rural communities against the unpredictable variations of climate change
Subscribe To Our Newsletter & Stay Updated
